Clinical Trials Logo

Helicobacter Pylori clinical trials

View clinical trials related to Helicobacter Pylori.

Filter by:

NCT ID: NCT03177629 Recruiting - Clinical trials for Immune Thrombocytopenia

H. Pylori Eradication for Moderate ITP

Start date: May 23, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy of H. pylori eradication for the treatment of chronic or persistent immune thrombocytopenic purpura (ITP) patients with moderate thrombocytopenia. This is a multi-center, open label, prospective randomized phase IIl study.

NCT ID: NCT02833363 Recruiting - Gastric Cancer Clinical Trials

Difference of Gastric Microbiota in the Process of Correa's Model.

Start date: July 2016
Phase: Phase 4
Study type: Observational

Helicobater pylori plays an important role in the development of gastric cancer. Eradication therapy can reducing the morbidity of gastric cancer, but can't totally prevent it especially when atrophy and more serious precancerous lesions already happened. Prior studies found the gastric bacterial difference among gastritis, intestinal metaplasia and gastric cancer. However, they didn't reach an agreement. Correa's model is widely accepted in the development of gastric cancer. The pathological change makes a more suitable environment for bacteria to overgrowth. This study are designed to analyze the gastric microbial difference of non-atrophic gastritis, atrophic gastritis, intestinal metaplasia, intraepithelial neoplasia and gastric cancer.

NCT ID: NCT00306280 Recruiting - Helicobacter Pylori Clinical Trials

Feasibility Study of Phototherapy System to Treat H Pylori

Start date: March 2006
Phase: N/A
Study type: Interventional

This purpose of this study is to determine whether phototherapy can be used to safely and effectively treat H pylori.

NCT ID: NCT00281047 Recruiting - Helicobacter Pylori Clinical Trials

The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy

Start date: January 2006
Phase: Phase 2/Phase 3
Study type: Interventional

FP-10 is a food ingredient derived from milk casein. FP-10 can inhibit H. pylori to attach to the gastric epithelium. FP-10 has been made clear to decrease the intragastric urease activity (which is assumed to be produced by H. pylori) measured by the urea breath test. FP-10 can also detach H. pylori from gastric epithelium. We have hypothesized that FP-10 increases the eradication rates by a triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.